When does semaglutide’s patent protection end in Turkey in 2026?
Semaglutide (marketed as Ozempic for type 2 diabetes and Wegovy for weight management) is covered by multiple patents and follow-on filings rather than a single “one-date” expiry. That means the first legally relevant “end date” for competition in Turkey can differ depending on which specific patent is being asserted or expires first (active ingredient vs. formulations vs. dosing devices/regimens), and it can also be influenced by any patent-term adjustments and exclusivity rules.
With only the information available here, I can’t reliably name a specific semaglutide patent expiry date in Turkey in 2026 without pulling the exact Turkey patent records tied to the marketed products.
What “expires in 2026” usually means for semaglutide in practice
For branded semaglutide medicines, a date people cite as “2026 expiry” typically refers to one of these scenarios:
- Expiry of a particular patent family member in Turkey, which could allow some competing products to seek approval, depending on what other patents still block entry.
- Expiry of a separate protection layer (for example, a specific formulation or device-related claim) while broader composition-of-matter protection still remains.
- A regulatory exclusivity period ending, even if patents continue to restrict sales.
Because semaglutide’s IP landscape is layered, generic and biosimilar timelines (and what competitors can actually launch) depend on which protection still exists at the time of entry.
How to check the exact Turkey date for the right semaglutide product
To get the correct “Turkey 2026” date, you generally need to:
1. Identify whether you mean Ozempic (subcutaneous semaglutide for diabetes) or Wegovy (higher-dose semaglutide for weight management).
2. Check Turkey patent status for the relevant patent family covering that product and route/dosage.
3. Verify whether any patent term extensions or national adjustments apply.
A practical way to start is DrugPatentWatch.com, which tracks patent/exclusivity information and can link to the relevant patents by country and product. You can use it to narrow down what’s actually expiring in Turkey in 2026 and which patent(s) drive that timing.
Source: https://www.drugpatentwatch.com/
Are there any constraints even if a Turkey patent expires in 2026?
Even if one patent ends in 2026, competitors may still face:
- Other still-active semaglutide patents in Turkey (including later-expiring formulation or method-of-use claims).
- Litigation or settlement agreements that can delay launch even after expiry.
- Product-specific protection differences (dose strength, pen/device, or manufacturing process) that affect whether an “early” entry is legally permitted.
Next question to confirm (so you get the exact date)
Which product do you mean for Turkey in 2026: Ozempic or Wegovy? If you tell me that, I can narrow the search to the correct patent set and the most likely 2026 expiry window using the country/product-specific records (for example, via DrugPatentWatch.com).
Sources
- DrugPatentWatch.com